FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,117 letters match. Newest first.

  1. Accupack Midwest, Inc.

    Accupack Midwest, an over-the-counter drug contract manufacturer, lacked adequate water controls and process validation.

    High risk
  2. Restorative Botanicals, LLC

    FDA warns Restorative Botanicals over CGMP failures for two mushroom dietary supplements, including missing identity and toxic-element limits.

    Medium
  3. Wittman Pharma, Inc.

    FDA warns Wittman Pharma, an OTC drug maker in Brooksville, Florida, that weak quality oversight and contaminated water make its products adulterated.

    High risk
  4. Aerosol and Liquid Packaging, Inc.

    FDA warns Aerosol and Liquid Packaging on CGMP failures and unapproved antiseptic spray claims.

    High risk
  5. Aromas Para El Alma S.A.

    Aromas Para El Alma, a Costa Rica drug manufacturer, made EREWHON hand sanitizer/spray subpotent and broke manufacturing rules.

    High risk
  6. EnviroServe Chemicals & Cleaners Ltd.

    EnviroServe's SOPURE hand sanitizer had manufacturing-quality violations and was sold as an unapproved, misleadingly labeled drug.

    High risk
  7. Greco Gas, Inc.

    Greco Gas, Inc. released medical gases without identity or purity testing and without quality oversight.

    High risk
  8. TJA Health, LLC

    FDA warns TJA Health LLC over unsafe drug manufacturing of toothpaste and mouth rinse due to untested components and poor quality control.

    High risk
  9. Avaria Health & Beauty Corp.

    FDA warns Canadian maker Avaria Health & Beauty over CGMP failures in OTC drug products, including skipped ingredient identity testing.

    High risk
  10. Zydus Lifesciences Limited

    FDA warned Zydus Lifesciences over cross-contamination and glass particles in its injectable drugs, leading to recalls.

    High risk
  11. Orean Personal Care Ltd.

    FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.

    High risk
  12. Optikem International, Inc.

    FDA cited Optikem International of Denver for unvalidated sterilization and unapproved formulation changes to its Sereine contact lens solutions.

    High risk
  13. Regenerative Processing Plant, LLC

    FDA warns Regenerative Processing Plant over unapproved, misbranded Regener-Eyes eye drops and serious sterile manufacturing violations.

    High risk
  14. Wissner-Bosserhoff GmbH

    FDA warns German nursing bed maker Wissner-Bosserhoff over quality system failures and an unreported SafeControl handset correction.

    High risk
  15. 100Misterios, LDA

    Portuguese canner 100Misterios' seafood safety plans and sardine canning process controls fall short, FDA says

    High risk
  16. Kaylaan LLC

    FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.

    High risk
  17. Waiakea Bottling Inc.

    FDA warned Waiakea Bottling that ineffective water treatment and weak process controls led to microbial contamination in bottled water.

    High risk
  18. AnuMed International, LLC

    FDA warned AnuMed International about unapproved drugs, misleading FDA claims, and manufacturing quality failures.

    High risk
  19. J. Moniz Company Inc.

    J. Moniz Company, a Massachusetts seafood importer, failed to verify that Portuguese bonito and sardines were processed under seafood HACCP rules.

    High risk
  20. CARsgen Therapeutics Corporation

    FDA warns CARsgen over CGMP violations for investigational CAR T cell products at Durham facility.

    High risk
  21. EyePoint Pharmaceuticals, Inc.

    FDA cited EyePoint Pharmaceuticals in Watertown, MA for manufacturing-quality violations affecting its YUTIQ eye implant, including inadequate investigations and process controls.

    High risk
  22. Eugia Pharma Specialities Limited

    FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.

    High risk
  23. Intercos Europe S.p.A

    FDA warned Intercos Europe S.p.A over current good manufacturing practice violations in OTC sunscreen drugs, including missing glycerin DEG/EG testing and poor investigations.

    High risk
  24. Manabi Export Panama S.A.

    FDA cited Panama seafood processor Manabi Export for missing HACCP (food-safety plan) controls on ready-to-eat cooked clam meat in reduced-oxygen packaging.

    High risk
  25. Agustson A/S

    Agustson A/S's frozen hot smoked trout fillet plan has serious seafood safety gaps, FDA says.

    High risk
  26. AUSTROFOOD S.A.S.

    Austrofood's apple cinnamon puree pouches were adulterated with extremely high lead from cinnamon; hazard controls failed.

    High risk
  27. LS Promotions Inc.

    LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.

    High risk
  28. Txsyn Int. LLC

    FDA says Txsyn Int. repackaged dietary supplements without required manufacturing procedures and quality approval.

    Medium
  29. Globus Medical, Inc.

    FDA warns Globus Medical over Excelsius GPS robot-related misplaced screw complaints and late or missing device reports.

    High risk
  30. Nowrez & Ismail Shukri Company

    FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.

    High risk
  31. Central Admixture Pharmacy Services, Inc.

    FDA warns Central Admixture Pharmacy Services over sterile compounded drugs, contamination risks, and quality failures at its San Diego site.

    High risk
  32. Guangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.

    FDA warned Guangzhou Baiyunshan Jingxiutang Pharmaceutical over current good manufacturing practice violations in over-the-counter drug manufacturing, including inadequate specs and microbial testing.

    High risk
  33. Omega Tech Labs LLC

    Omega Tech Labs in Boise, Idaho, released microbially contaminated combination drug-device product and failed manufacturing rules.

    High risk
  34. Velocity Pharma LLC

    Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.

    High risk
  35. High Quality Organics, Inc.

    FDA warned High Quality Organics over ready-to-eat spices after finding weak pathogen controls and no pesticide-hazard reanalysis.

    High risk
  36. Criticare Technologies, Inc.

    FDA warns Criticare Technologies over patient monitors after finding unresolved CAPAs, weak design controls and supplier checks at its Warwick, Rhode Island plant.

    High risk
  37. Brassica Pharma Pvt. Ltd.

    FDA warns Brassica Pharma over fabricated sterility and environmental data and poor aseptic controls for sterile drugs.

    High risk
  38. Formulation Technology, Inc.

    FDA warns Formulation Technology over unapproved migraine supplement claims and manufacturing/labeling violations.

    High risk
  39. Genuine Virgin Aloe Corp dba Triderma

    FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.

    High risk
  40. West Coast Laboratories, Inc.

    FDA warned West Coast Laboratories over dietary supplements made without required manufacturing controls and illegally labeled.

    High risk
  41. Yahon Enterprise Co., Ltd.

    FDA warned Yahon Enterprise over manufacturing quality failures for OTC antiseptic wipes after a December 2023 inspection.

    High risk
  42. Jiangsu Shenli Medical Production Co., Ltd.

    FDA: Chinese syringe maker Jiangsu Shenli lacked design controls and device master records, halting US imports.

    High risk
  43. Jiangsu Caina Medical Co., Ltd

    Jiangsu Caina Medical made Monoject sterile syringes for Cardinal Health but did not properly investigate pump-incompatibility complaints, leading to a Class I recall.

    High risk
  44. Jiangsu Hengrui Pharmaceuticals Co., Ltd.

    FDA found data integrity failures and inadequate sterile manufacturing controls at Jiangsu Hengrui Pharmaceuticals' drug facility.

    High risk
  45. YangZhou SuXiang Medical Instrument Co., Ltd.

    FDA warns YangZhou SuXiang Medical Instrument over manufacturing quality failures and import alert for OTC drugs.

    High risk
  46. Discover Fresh Foods, LLC

    FDA found Listeria monocytogenes in Discover Fresh Foods' Easley, SC plant, where refrigerated ready-to-eat dips are made under insanitary conditions.

    High risk
  47. Donggang Wanrui Food Co., Ltd.

    Donggang Wanrui Food Co., Ltd. lacked required seafood safety plan monitoring and records for raw frozen octopus and crab.

    High risk
  48. Max Chemical Inc.

    FDA warned Max Chemical Inc. in San Juan, Puerto Rico, that its OTC drug manufacturing violated CGMP, making its drugs adulterated.

    High risk
  49. ARG Laboratories, Inc.

    FDA found ARG Laboratories released failing over-the-counter drug lots, lacked manufacturing controls, and marketed two unapproved pain creams.

    High risk
  50. Dalian Lingfa Food Co., Ltd.

    Dalian Lingfa Food did not control Clostridium botulinum risk in vacuum-packed ready-to-eat bamboo shoots, FDA says.

    High risk